Risvutatug

HS-20093 Antibody (GSK5764227 Antibody) is an antibody targeting B7-H3, which can be used to synthesize the ADC HS-20093. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors[1][2][3].

Product Specifications

CAS Number

[3042848-87-0]

Product Name Alternative

HS-20093 Antibody; GSK5764227 Antibody

UNSPSC

12352203

Target

ADC Antibody; CD276/B7-H3

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.55

Smiles

[Risvutatug]

References & Citations

[1]J. Wang, et al., OA04.06 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001) . Volume 19, Issue 10, Supplement S17, 2024|[2]Lu Xie, et al., ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma. Journal of Clinical Oncology. 42 (16), 2024|[3]Jie Wang, et al., ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor. Journal of Clinical Oncology. 41 (16), 2023.